Category: Data Integrity

Software Validation

Identification of Software Validation Shortcomings

GMP/GCP compliance failures in the drug product segment are no longer identified as the ‘software not being validated for its intended use’, but rather the deficiencies are now linked to the predicate GMP requirements based on FDA’s stated focus in 2010.

Read More »

AveXis’s New Gene Therapy Approved but New Questions Are Raised

FDA issued a particularly harsh press release on August 6, 2019 addressing the data accuracy issues with the BLA for the gene therapy product, Zolgensma, which was approved by FDA on May 24, 2019. It seems the FDA is using them, and more importantly their parent company Novartis, as an example of what not to do.

Read More »

Can’t find what you are looking for? Contact us.